p36 and p35 are distinct but related proteins that share many structural and biochemical features which were first identified as major substrates for protein-tyrosine kinases. Subsequently, both proteins have been shown to be Ca2+-, phospholipid-, and F-actin-binding proteins that underlie the plasma membrane and are associated with the cortical cytoskeleton. Recent reports have claimed that these proteins function as lipocortins, i.e., phospholipase A2 inhibitors that mediate the anti-inflammatory action of glucocorticoids. To investigate this possibility and to learn more about the functions of p36 and p35, we used human-specific anti-p36 and anti-p35 monoclonal antibodies to determine whether the expression or secretion of either protein was inducible by dexamethasone in the human U-937 myeloid cell line and in other human cell types. Additionally, we examined the levels of mRNA for both proteins. No effect of dexamethasone was observed on p36 or p35 expression at either the mRNA or protein level, nor were these proteins secreted under any of the culture conditions investigated. However, it was observed that in these cells the rate of synthesis and accumulation of both proteins was increased when the U-937 cells were induced to differentiate in culture to adherent macrophagelike cells. This offers a model system with which to study the control of p36 and p35 expression.
p36 and p35 were initially identified as major substrates for protein-tyrosine kinases (9, 14, 15, 20, 39, 52, 53, 58) . Subsequently, their biochemical properties have been investigated in great detail, and this has led to their being termed calpactin I (p36) and calpactin II (p35) (21) or lipocortin I (p35) and lipocortin II (p36) (37) . For clarity we will use the names p36 and p35 throughout. What has emerged from these studies is that the two proteins share many structural and functional features. First, both proteins bind Ca2 , anionic phospholipids, and F-actin (12, 15, 19, 21, 22) . Second, p35 and p36 are both abundant cellular proteins which are localized to the cortical cytoskeleton underlying the plasma membrane (24, 27, 47, 51) . Third, p35 and p36 are both able to inhibit phospholipase A2 (PLA2) in vitro (11, 28, 36, 37, 49) . Finally, the structure of p35 and p36 predicted from cDNA clones has revealed an overall structural similarity and -50% amino acid identity (37, 42, 57, 62) . Each protein has a short unique N-terminal sequence followed by four copies of a 75-amino-acid repeat. This repeat has been found in several other Ca2+-and phospholipid-binding proteins with similar properties, and on this basis it has been proposed that this family of proteins be called annexins (18) .
Two distinct functions for p36 and p35 have been proposed. First, their abundance, subcellular localization, and binding properties suggest that their function in vivo is in part structural and involves interaction with the plasma membrane and underlying protein components of the cortical skeleton. In this context, p36 has also been implicated in the secretion process by its ability to promote membrane vesicle fusion in vitro in the presence of Ca2+ (13) .
Second, their ability to inhibit PLA2 in vitro suggests that p36 and p35 might function to regulate PLA2 in vivo. Evidence that PLA2 activity can be regulated in vivo comes from the ability of glucocorticoid steroids, such as dexamethasone, to suppress inflammation (17) . The inflammatory response is induced by leukotrienes, prostaglandins, and other eicosanoid compounds, which are synthesized from arachidonic acid released by PLA2 hydrolysis of phospholipids. The mechanism by which glucocorticoids act to reduce arachidonic acid release is not fully understood, but there is evidence implicating a group of proteins that are secreted from macrophages in response to glucocorticoids and that can act on other cells to inhibit arachidonic acid release (2, 16, 17, 32, 35) . These proteins have been termed lipocortins (previously known as either macrocortins or lipomodulins). Lipocortins are formally defined as proteins whose production and secretion is induced by glucocorticoids and which act extracellularly to inhibit eicosanoid production. Lipocortin activity can be measured as an inhibition of eicosanoid release both in cell culture and in model inflammation response systems in animals. There is some evidence that the activity of lipocortins can be modulated by phosphorylation (31, 33) . In consequence, it is presumed that lipocortins act to regulate PLA2 activity. However, there is no evidence from the biological assays that lipocortins act directly on PLA2 itself rather than through a pathway leading to PLA2.
On the assumption that lipocortins would act directly to inhibit PLA2, Pepinksy and his colleagues purified a polypeptide with lipocortin activity from rat peritoneal exudate using a PLA2 inhibition assay (49) . This led to the isolation and subsequent cloning of lipocortin I, which was then shown to be identical to p35 (62) . The level of lipocortin I mRNA was found to be increased in peritoneal cells following dexamethasone treatment, but no change in protein level was observed (62) . Similar increases in lipocortin I mRNA were reported to occur when the U-937 human monocytic cell line was treated with dexamethasone (62) . In keeping with the idea that this protein is a true lipocortin, recombinant lipocortin I has been shown to have anti-inflammatory activity in an in vivo assay (6) . In a later study, a second polypeptide with lipocortin activity was purified that proved to be identical to p36 (37) . Lipocortin II behaves similarly to lipocortin I in the PLA2 inhibition assay (37) .
Although these studies suggest a role for lipocortins I and II in the anti-inflammatory effects of steroids, there are a number of facts that are inconsistent with this notion. First, in many cell types p35 and p36 are very abundant proteins (21) . Thus, steroids would not be expected to induce rapid changes in p35 or p36 levels, although secretion of preformed protein could occur in response to steroids. Second, p35 and p36 have been shown to inhibit PLA2 by an indirect mechanism involving sequestration of phospholipid substrate rather than by direct interaction with the enzyme (11, 28) . Third, neither p35 nor p36 has a conventional signal peptide for entry into the cellular secretion pathway (37, 42, 57, 62) , which precludes secretion of these proteins by a conventional mechanism.
In an attempt to understand more about the function of p36 and p35 and to determine whether their expression could be modulated by steroids in a fashion consistent with a role as lipocortins, we (60) and resolved on 15% sodium dodecyl sulfate-polyacrylamide gels. Where indicated, gels were enhanced with diphenyloxazole before being dried and exposed to presensitized Kodak XAR X-ray film. Peptide mapping was done as described previously (1).
Western blotting. Immunoblotting of p36 was performed exactly as described by Gould et al. (25) using a polyclonal anti-chicken p36 serum (10) .
Northern (RNA) blot analysis. Total cellular RNA was isolated by the guanidine thiocyanate method (5). Nitrocellulose (Schleicher & Schuell, Inc., Keene, N.H.) blots were made from formaldehyde gels (1 or 1.4% agarose) and hybridized as described by Maniatis et al. (44) . The blots were washed to a final stringency of 0.2x SSPE at 420C. Hybridization probes were labeled by nick translation (44) . The p36 probe was a 733-base-pair HindIII-XbaI fragment from the murine cDNA clone isolated by Saris et al. (57) . A human p35 clone was isolated by screening a HeLa cell cDNA library provided by Steven Hanks (The Salk Institute) (29) with a 32-mer complementary to nucleotides -5 to 27 of p35 as reported by Wallner et al. (62) . The p35 probe used for Northern analysis was the 1,301-base-pair AatII-EcoRI fragment, which encompasses nearly the entire human p35 coding sequence. A 168-base-pair BamHI-PvuII fragment from the coding region of human metallothionein IIA was provided by Michael Karin (University of California, San Diego) (41) . For densitometry of Northern blots, ,-actin mRNA levels were used as an internal standard. The probe was the entire cDNA insert described by Cleveland et al. (7) . Densitometric scanning of autoradiograms and signal inte- 
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Characterization of MAb 74/3 (anti-human p35). A MAb against human p35 (MAb 74/3) was isolated by screening hybridoma supernatants for their ability to immunoprecipitate a 35-kilodalton protein from human cell lines. As shown by analysis of immunoprecipitates made from A431 cells, the protein recognized by MAb 74/3 migrates on reducing sodium dodecyl sulfate-polyacrylamide gels with a slightly slower mobility than human p36 (Fig. 1 ). This mobility is characteristic of p35 as shown by Glenney et al. (21, 24) and is predicted from a sequence comparison of the two proteins (37, 57) . To characterize this protein further, the bands immunoprecipitated by the anti-p36 MAb (MAb B1/107) and MAb 74/3 were excised from the gel shown in Fig. 1 were exposed for a 10-fold-longer period of time (panel C). In addition, there was no alteration in the amounts of labeled p36 or p35 immunoprecipitated from these cells. To determine whether our inability to detect such changes was due to our culture or labeling conditions, many experimental variables were examined. For example, U-937 cells were either labeled to equilibrium for 16 h with [35S]methionine in the presence or absence of dexamethasone, or they were incubated for 16 h with dexamethasone and then pulse-labeled with [35S]methionine for 30 min prior to immunoprecipitation with the p36-specific MAb D1/274 (Fig. 3) . The former condition provides a measure of the total amount of immunoprecipitable p36 present, whereas the latter reflects the rate at which it is being synthesized. Again, there was no detectable change in the expression of p36, and no p36 was detected in the culture supernatants (Fig. 3) . We have performed these experiments under different labeling conditions, with variable amounts of dexamethasone, with or without TPA, and for different lengths of dexamethasone treatment time. No effect of dexamethasone treatment on either p36 or p35 expression was ever observed.
To confirm that glucocorticoids have no effect on the expression of the p36 and p35 genes in U-937 cells, we examined the mRNA levels in cells after dexamethasone treatment. Incubation of the cells for 1 or 6 h with dexamethasone or TPA or both had little effect on the levels of p35 mRNA (Fig. 4A) . Densitometric scans of Northern blots showed that neither p36 nor p35 mRNA levels change in response to dexamethasone (Fig. 4B) . TPA caused a slight increase in the levels of both mRNAs, but dexamethasone plus TPA showed no increase over TPA alone. As a control, these blots were also probed for metallothionein "A mRNA expression. Glucocorticoids are known to induce metallothionein in a number of different cell types (40, 54) , and in U-937 cells we found that the level of metallothionein ,A mRNA increased -3-fold when the cells were treated for 6 h with dexamethasone and -29-fold when the cells were treated for 6 h with both dexamethasone and TPA. Therefore, the failure of dexamethasone to induce p36 and p35 expression is not due to these cells being refractory to the effects of glucocorticoids.
It should be noted that treatment of U-937 cells for long periods of time (>16 h) with high concentrations of dexamethasone (10 ,uM) did occasionally result in the appearance of p36 and p35 in the culture supernatants. Extensive experiments with p36 subsequently demonstrated that this material is almost certainly associated with cell debris and results from cell death due to the prolonged steroid treatment 16 h did not alter p36 expression (Fig. 3) .
The effects of dexamethasone treatment on the phosphorylation of both proteins was also examined, and no detectable change was ever observed (data not shown).
Modulation of p36 and p35 expression in differentiating U-937 cells. U-937 cells are an immature monocytic cell line that can be induced to differentiate into macrophagelike cells by treatment with TPA (45, 48) . To determine whether the levels of p36 or p35 could be modulated during differentiation, U-937 cells were treated with 20 ng of TPA per ml for up to 48 h, pulse-labeled for 30 This increase in the rate of p36 and p35 synthesis was paralleled by an increase in the level of protein as detected by immunoprecipitation from cells that have been labeled to equilibrium (Fig. 3) or by Western blotting of protein (data not shown) and by an increase in the level of mRNA (Fig. 4) .
Modulation of p36 and p35 in differentiating HL-60 cells. Finally, we wished to determine whether the modulation of p36 and p35 during U-937 cell differentiation was found iñ days.
other cell systems and whether it might be a specific effect of TPA treatment. In our earlier experiments we had examined the effects of long-term TPA treatment of several nonhematopoietic cell lines and found that TPA treatment of AG1523, HEp-2, and A431 cells for 16 to 24 h had no effect on the levels of p36 or p35 (Fig. 5) , although these cells respond to TPA as determined by other biological assays. In contrast to these adherent cell lines, HL-60 cells, like U-937 cells, can also be induced to differentiate from a promyelocytic phenotype to macrophagelike cells with TPA treatment. However, unlike U-937 cells, HL-60 cells are bipotential and can also be induced to differentiate into granulocytes by treatment with retinoic acid or DMSO (8, 45, 55) . It can be seen again that treatment of U-937 cells with TPA resulted in an increase in the rate of p36 and p35 synthesis (Fig. 7) . In a similar manner, it was found that the rate of p35 synthesis increased in HL-60 cells induced to differentiate into macrophages by exposure to TPA. In contrast, retinoic acid treatment, which results in differentiation into granulocytes, slightly decreased the rate of p35 synthesis. Curiously, we were unable to detect p36 in either differentiated or undifferentiated HL-60 cells.
To determine whether this regulation of p35 and p36 expression was at the level of mRNA accumulation, Northern analysis of these cells was performed. No p36 mRNA was detectable in HL-60 cells treated with DMSO or retinoic acid (Fig. 8) . In contrast, p36 mRNA was detected in U-937 cells, and the amount was found to increase in cells treated with DMSO, which results in the differentiation of U-937 cells into macrophages (46) . This also shows that induction of p36 is not specific to TPA.
In general, increases in the rate of p36 and p35 synthesis as detected by immunoprecipitation were always paralleled by an increase in the level of mRNA. Furthermore, when it was examined, it was found that the level of p36-associated light-chain (pll, also known as plO or calpactin I light-chain) ( (Fig. 1 to 5 ). Wallner et al. (62) (11) performed titration experiments and showed that p36 and p35 did not inhibit the activity of PLA2 when the phospholipids were present in excess. Because p36 and p35 apparently act by a mechanism of substrate competition, this raises doubts as to whether they could block the activity of PLA2 in vivo by a similar mechanism.
(iv) The activity of lipocortins is supposedly regulated by phosphorylation so that when phosphorylated they no longer inhibit PLA2 (31, 33) . Although it has been well established that both p36 and p35 can be phosphorylated on serine and tyrosine residues (9, 14, 15, 26, 39, 52, 58) , only a small percentage (up to 5%) of molecules become phosphorylated at any one time. There is some evidence that phosphorylation of p35 and p36 alters their phospholipid-binding properties, although the effects on the two proteins seem to be contrary (50, 59) . In preliminary experiments we were not able to detect any changes in phosphorylation of these proteins in dexamethasone-treated cells (data not shown).
(v) Experiments have been performed to determine whether purified p36 or p35 can function in vivo in antiinflammatory assays. The results from this type of analysis are contradictory. Cirino et al. (6) have reported that bacterially expressed p35 (lipocortin I) will inhibit eicosanoid release when used in a guinea pig lung infusion system. However, the authors state that they are not able in this assay to distinguish between p35 acting as a substrate competitor or as an enzyme inhibitor. Northup et al. (48a) have found that purified placental p35 does not act as an anti-inflammatory agent in a paw edema assay, nor will it inhibit the release of arachidonate from zymosan-stimulated mouse macrophages.
In sum, these arguments support the notion that p35 and p36 do not function as steroid-inducible lipocortins. If this is true, an explanation is needed for the fact that U-937 cells have been reported to produce lipocortin activity (30) . It could be argued that our failure to detect glucocorticoid induction of p35 and p36 is due to a variable response of different U-937 clones. However, while we did not confirm that U-937 cells produce lipocortin under our conditions, Bronnegard et al. (3) failed to observe dexamethasone induction of p35 mRNA in primary human macrophages, which are known to produce lipocortin. If p36 and p35 are not lipocortins, what then is the identity of lipocortin? One possibility is that there is another protein(s), which is both glucocorticoid inducible and secreted, that acts indirectly to regulate PLA2 activity. Such a protein would have been missed in the assay that was used to purify lipocortin. It should also be borne in mind that there may be additional mechanisms in vivo through which glucocorticoids can inhibit PLA2. For instance, interleukin 1 expression is decreased by glucocorticoids in U-937 cells, and this would have an anti-inflammatory effect (43) .
Function of p36 and p35 other than as lipocortins. The increase in p36 and p35 expression in U-937 cells induced to differentiate into macrophages supports the suggestion that they might play a role in membrane movement or cell attachment or both by interacting with the cytoskeleton and overlying plasma membrane. Unlike their precursors, which grow in suspension culture, macrophages are adherent cells which exhibit extensive membrane fluidity in the form of ruffling and exocytosis and which respond to chemoattractants. Support of this function for these proteins has come from studies by Carter et al. (4) . They have demonstrated that limb buds from 5-day-old chicks express very low levels of p36 protein but that if these are cultured in vitro for 48 h, there is a dramatic increase in the level of protein. Furthermore, this increase is dependent upon the cells being grown on a substratum, as culture in semisolid medium does not result in increased p36 expression.
Here we have described the isolation of a MAb specific for human p35 (MAb 74/3). The availability of reagents (see also references 38 and 63) and molecular probes should allow a detailed investigation into the control of p36 and p35 expression and help to elucidate their function in vivo. The finding of an in vitro culture system in which the expression of these proteins is regulated will be useful for future experiments. 
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